Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2013 - 2019)
Ultragenyx Pharmaceutical's (RARE) quarterly Current Deferred Revenue came in at $69000.0 in Q1 2019, down 90.46% year-on-year from $723000.0 in Q1 2018, and down 94.45% on a QoQ basis from $1.2 million in Q2 2018.
Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2013 - 2019) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 7 years of Current Deferred Revenue data on file, last reported at $69000.0 in Q1 2019.
- On a quarterly basis, Current Deferred Revenue fell 90.46% year-over-year to $69000.0 in Q1 2019; TTM through Mar 2019 was $69000.0, a 90.46% decrease from a year earlier, with the FY2017 full-year figure at $6.0 million, up 1655.43% from the prior year.
- Current Deferred Revenue for Q1 2019 stood at $69000.0, down from $1.2 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for RARE reached as high as $6.0 million in Q4 2017 and fell as low as $69000.0 in Q1 2019.
- Historically, Current Deferred Revenue has averaged $794000.0 across 5 years, with a median of $328000.0 in 2016.
- Across the five-year window, Current Deferred Revenue jumped 1655.43% in 2017 and sank 90.46% in 2019, its largest moves.
- Year by year, Current Deferred Revenue stood at $192000.0 in 2015, then jumped by 77.6% to $341000.0 in 2016, then soared by 1655.43% to $6.0 million in 2017, then sank by 79.22% to $1.2 million in 2018, then tumbled by 94.45% to $69000.0 in 2019.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $69000.0 in Q1 2019, $1.2 million in Q2 2018, and $723000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ultragenyx Pharmaceutical | 2.72 Bn | 2.31 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 69,000.00 |
| Jun 30, 2018 | 1.24 Mn |
| Mar 31, 2018 | 723,000.00 |
| Dec 31, 2017 | 5.99 Mn |
| Sep 30, 2017 | 695,000.00 |
| Jun 30, 2017 | 669,000.00 |
| Mar 31, 2017 | 637,000.00 |
| Dec 31, 2016 | 341,000.00 |
| Sep 30, 2016 | 328,000.00 |
| Jun 30, 2016 | 315,000.00 |
| Mar 31, 2016 | 303,000.00 |
| Dec 31, 2015 | 192,000.00 |
| Sep 30, 2015 | 163,000.00 |
| Jun 30, 2015 | 155,000.00 |
| Mar 31, 2015 | 90,000.00 |
| Dec 31, 2014 | 85,000.00 |
| Sep 30, 2014 | 80,000.00 |
| Jun 30, 2014 | 75,000.00 |
| Mar 31, 2014 | 78,000.00 |
| Dec 31, 2013 | 78,000.00 |